Cargando…

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis

Objective: It is well-known that initiation of fingolimod induces a transient decrease of heart rate. However, the underlying cardiac autonomic regulation is poorly understood. We aimed to investigate the changes of autonomic activity caused by the first dose of fingolimod using a long-term multiple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Kai, Konofalska, Urszula, Akgün, Katja, Reimann, Manja, Rüdiger, Heinz, Haase, Rocco, Ziemssen, Tjalf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643482/ https://www.ncbi.nlm.nih.gov/pubmed/29075174 http://dx.doi.org/10.3389/fnins.2017.00540

Ejemplares similares

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
por: Sehr, Tony, et al.
Publicado: (2020)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses
por: Woopen, Christina, et al.
Publicado: (2022)

Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson’s disease
por: Li, Kai, et al.
Publicado: (2017)

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation
por: Thomas, Katja, et al.
Publicado: (2017)

S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review
por: Constantinescu, Victor, et al.
Publicado: (2022)

Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease
por: Thomas, Katja, et al.
Publicado: (2014)

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis
por: Racca, Vittorio, et al.
Publicado: (2019)

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Trigonometric Regressive Spectral Analysis Reliably Maps Dynamic Changes in Baroreflex Sensitivity and Autonomic Tone: The Effect of Gender and Age
por: Reimann, Manja, et al.
Publicado: (2010)

A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes
por: Limmroth, Volker, et al.
Publicado: (2020)

The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis
por: Petsas, Nikolaos, et al.
Publicado: (2019)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Digital Twins for Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2021)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020)

Intermittent Atrioventricular Block following Fingolimod Initiation
por: Gialafos, E., et al.
Publicado: (2014)

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
por: Proschmann, Undine, et al.
Publicado: (2021)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study
por: Reimann, Manja, et al.
Publicado: (2013)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Autonomic Dysfunction in Wilson's Disease: A Comprehensive Evaluation during a 3-Year Follow Up
por: Li, Kai, et al.
Publicado: (2017)

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Determination of Baroreflex Sensitivity during the Modified Oxford Maneuver by Trigonometric Regressive Spectral Analysis
por: Gasch, Julia, et al.
Publicado: (2011)

Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
por: Bianco, Assunta, et al.
Publicado: (2021)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study
por: Limmroth, Volker, et al.
Publicado: (2017)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pofnl2c7pgbf91tqntst9sst9c